<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/29019/adjuvant-therapy-in-rcc-very-controversial-but-needs-continual-development-sunitinib-therapy-is-a-reasonable-approach-to-take?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Adjuvant Therapy In RCC: Very Controversial But Needs Con...

Name: Adjuvant Therapy In RCC: Very Controversial But Needs Con...
Uploaded: 2019-06-04T12:36:43
Duration: 2 min 17 s
Description: Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses Adjuvant Therapy In RCC: Very Controversial But Needs Continual Development, Sunitinib Therapy Is A Reasonable Approach To Take.

Adjuvant Therapy In RCC: Very Controversial But Needs Continual Development, Sunitinib Therapy Is A Reasonable Approach To Take

00:02:17

Annual Meeting

3 years 33 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/29019/adjuvant-therapy-in-rcc-very-controversial-but-needs-continual-development-sunitinib-therapy-is-a-reasonable-approach-to-take?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/29019/adjuvant-therapy-in-rcc-very-controversial-but-needs-continual-development-sunitinib-therapy-is-a-reasonable-approach-to-take?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/29019/adjuvant-therapy-in-rcc-very-controversial-but-needs-continual-development-sunitinib-therapy-is-a-reasonable-approach-to-take?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/29019?channelName=AnnualCancerMeeting"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190604003643_394b/video_190604003643_394b.jpg?cache=15669162741678829655">Adjuvant Therapy In RCC: Very Controversial But Needs Continual Development, Sunitinib Therapy Is A Reasonable Approach To Take</a>

Link (BBCode):

[url=https://oncologytube.com/v/29019?channelName=AnnualCancerMeeting][img]https://oncologytubecom.cdn.ypt.me/videos/video_190604003643_394b/video_190604003643_394b.jpg?cache=15669162741678829655[/img]Adjuvant Therapy In RCC: Very Controversial But Needs Continual Development, Sunitinib Therapy Is A Reasonable Approach To Take[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Kidney

Description:

Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses Adjuvant Therapy In RCC: Very Controversial But Needs Continual Development, Sunitinib Therapy Is A Reasonable Approach To Take.